These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10085409)

  • 21. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
    Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
    Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential application of ribozymes for the treatment of hematological disorders.
    James HA
    J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribozyme: a clinical tool.
    Khan AU
    Clin Chim Acta; 2006 May; 367(1-2):20-7. PubMed ID: 16426595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribozyme gene therapy: applications for molecular medicine.
    Lewin AS; Hauswirth WW
    Trends Mol Med; 2001 May; 7(5):221-8. PubMed ID: 11325634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of hammerhead ribozymes to modulate endogenous gene expression for functional studies.
    Fritz JJ; Lewin A; Hauswirth W; Agarwal A; Grant M; Shaw L
    Methods; 2002 Oct; 28(2):276-85. PubMed ID: 12413427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV and Ribozymes.
    Scarborough RJ; Gatignol A
    Adv Exp Med Biol; 2015; 848():97-116. PubMed ID: 25757617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic potential of ribozymes.
    James HA; Gibson I
    Blood; 1998 Jan; 91(2):371-82. PubMed ID: 9427689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing ribozymes for the inhibition of gene expression.
    Bramlage B; Luzi E; Eckstein F
    Trends Biotechnol; 1998 Oct; 16(10):434-8. PubMed ID: 9807841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
    Pavco PA; Bouhana KS; Gallegos AM; Agrawal A; Blanchard KS; Grimm SL; Jensen KL; Andrews LE; Wincott FE; Pitot PA; Tressler RJ; Cushman C; Reynolds MA; Parry TJ
    Clin Cancer Res; 2000 May; 6(5):2094-103. PubMed ID: 10815937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudoknot interaction-mediated activation of type I hammerhead ribozyme: a new class of gene-therapeutic agents.
    Kuriyama M; Kondo Y; Tanaka Y
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(7):466-80. PubMed ID: 24972011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo.
    Taylor NR; Kaplan BE; Swiderski P; Li H; Rossi JJ
    Nucleic Acids Res; 1992 Sep; 20(17):4559-65. PubMed ID: 1408757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes.
    Fei Q; Zhang H; Fu L; Dai X; Gao B; Ni M; Ge C; Li J; Ding X; Ke Y; Yao X; Zhu J
    Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):466-77. PubMed ID: 18535745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro cleavage activity of the ribozymes constructed specifically for the second exons of pro alpha I and III collagen genes].
    Zhu JY; Zhu B; Xu B; Zhang T; Chen D; Tang B; Li XQ
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jun; 24(6):653-5. PubMed ID: 15201081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-oncogene ribozymes for cancer gene therapy.
    Irie A; Kijima H; Ohkawa T; Bouffard DY; Suzuki T; Curcio LD; Holm PS; Sassani A; Scanlon KJ
    Adv Pharmacol; 1997; 40():207-57. PubMed ID: 9217927
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic applications of group I intron-based trans-splicing ribozymes.
    Lee CH; Han SR; Lee SW
    Wiley Interdiscip Rev RNA; 2018 May; 9(3):e1466. PubMed ID: 29383855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of ribozymes in haematological disorders.
    James HA
    Expert Opin Investig Drugs; 2000 May; 9(5):1009-20. PubMed ID: 11060723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.